Critical Junctures in Genetic Medicine: The Transformation of DNA Lab Science to Commercial Pharmacogenomics

Stephanie S. Turner University of Houston - Downtown

Abstract

Genetic medicine, which consists mostly of screening tests for certain heritable diseases but may soon include treatment for heritable diseases based on molecular genetics, is made possible by two critical junctures in the textual representation of medical subjects. The first is the transformation of organic human genetic material into computationally sophisticated data, and the second is the subsequent conversion of these vast quantities of genetic data into intellectual property through gene patenting and screening-test marketing. This article examines these representational changes in medical subjects through an intertextual and rhetorical analysis of the documentation surrounding the discovery, patenting, and marketing of the breast cancer susceptibility gene BRCA1 by the biotechnology company Myriad Genetics. It identifies the impact of these changes on the analysis of the risks and benefits associated with screening for heritable diseases.

Journal
Journal of Business and Technical Communication
Published
2005-07-01
DOI
10.1177/1050651905275619
CompPile
Search in CompPile ↗
Open Access
Closed
Topics
Export

Citation Context

Cited by in this index (3)

  1. Journal of Business and Technical Communication
  2. Journal of Business and Technical Communication
  3. Journal of Technical Writing and Communication

References (56) · 3 in this index

  1. Policy statements
  2. Report 9 of the Council on Scientific Affairs: Patenting of genes and their mutations
  3. 10.1038/nrg909
  4. Journal of Business and Technical Communication
  5. Journal of Business and Technical Communication
Show all 56 →
  1. 10.1172/JCI20113
  2. Mission and guidelines
  3. Policy on genetic testing for breast cancer susceptibility
  4. Brenner v. Manson, 383 U.S. 519 (1966).
  5. 10.1038/35042087
  6. 10.1056/NEJMra012577
  7. NewScientist.com
  8. 10.1038/35093580
  9. 10.1086/301784
  10. 10.1080/1360083042000190625
  11. 10.1111/1467-9566.00151
  12. Health care and intellectual property rights
  13. Wetwares: Experiments in postvital living
  14. Journal of Business and Technical Communication
  15. Emory Law Journal
  16. 10.1162/152651602760249969
  17. 10.1126/science.7939630
  18. 10.1126/science.2270482
  19. Texas Intellectual Property Law Journal
  20. 10.1126/science.274.5287.496
  21. Genetics researchers collaborate with Utah families
  22. 10.2307/378062
  23. The century of the gene
  24. 10.1002/(SICI)1096-8628(19970822)71:3<289::AID-AJMG8>3.0.CO;2-P
  25. International Intellectual Property Institute
  26. MAMM: Women, Cancer, and Community
  27. 10.1126/science.7545954
  28. 10.1353/con.2004.0022
  29. Moore v. Regents of the University of California, 249 Cal. (1990).
  30. 10.1016/S0065-2660(03)50002-5
  31. 10.1177/030631295025001004
  32. Research
  33. Understanding inherited breast and ovarian cancer
  34. Annual report
  35. Myriad Genetics identifies six new drug targets
  36. Information for healthcare professionals: Benefits of BRACAnalysis® testing
  37. Myriad Genetics and LabCorp form exclusive predictive medicine marketing alliance
  38. 10.1038/35080583
  39. Gattaca
  40. 10.1126/science.278.5340.1068
  41. 10.1162/152651602760250011
  42. White paper on proteomics and genomics: Meeting utility requirements
  43. 10.1126/science.8430309
  44. Linked breast and ovarian cancer susceptibility gene
  45. Myriad Genetics: Executing the vision of molecular medicine
  46. 10.1353/pmc.2003.0010
  47. Biomedia
  48. Federal Register
  49. 10.1136/bmj.323.7318.888
  50. Health Law Journal
  51. 10.1056/NEJMra012284